High Risk at Chocolate: Undeclared Allergens Found

chocolatePhoto byQuick PSonUnsplash

The recent recall of the Marabou Sea Salt Chocolate Bar by BonBon NYC LLC has been classified as a "Class 1" recall by the U.S. Food and Drug Administration (FDA), indicating a high risk of serious health consequences or death. The FDA found that the chocolate bars may contain undeclared almonds, wheat, and nuts. These bars were sold in BonBon retail stores in New York City and are produced in Sweden.

In addition to the Marabou Sea Salt Chocolate Bar recall, the FDA has issued recalls for other food products in September. These include the 7-Eleven Fudge Brownie due to undeclared walnuts, and Dark Chocolate Filled Mini Waffle Cones due to undeclared milk after a customer reported an allergic reaction. Other recalls include whole cantaloupes, eggs, and Shiso Katsuo Ninniku & Miso Katsuo Ninniku due to various contamination concerns.

It is crucial for consumers to stay informed about food recalls to ensure their safety and well-being. Consumers are urged to check their pantries and refrigerators for any of the recalled products and to dispose of them or return them to the place of purchase for a full refund. The FDA continues to monitor food safety and issue timely recalls to protect the public from potential health risks. It is essential for individuals with food allergies or sensitivities to be especially vigilant about checking ingredient labels and staying updated on product recalls to prevent any adverse reactions.

Staying informed about food recalls can ensure that consumers make safe choices when purchasing and consuming food products. By actively following updates from the FDA and other regulatory agencies, individuals can help safeguard their health and well-being. It is important for both the public and food manufacturers to work together in maintaining food safety standards and minimizing the risks associated with contaminated or allergen-containing products.

Source:

https://www.newsweek.com/chocolate-recall-update-fda-risk-update-1953833